Digestive Diseases and Sciences

, Volume 60, Issue 4, pp 1024–1030 | Cite as

Total Body Weight Loss of ≥10 % Is Associated with Improved Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis

  • Lisa M. Glass
  • Rolland C. DicksonEmail author
  • Joseph C. Anderson
  • Arief A. Suriawinata
  • Juan Putra
  • Brian S. Berk
  • Arifa Toor
Original Article



Given the rising epidemics of obesity and metabolic syndrome, nonalcoholic steatohepatitis (NASH) is now the most common cause of liver disease in the developed world. Effective treatment for NASH, either to reverse or prevent the progression of hepatic fibrosis, is currently lacking.


To define the predictors associated with improved hepatic fibrosis in NASH patients undergoing serial liver biopsies at prolonged biopsy interval.


This is a cohort study of 45 NASH patients undergoing serial liver biopsies for clinical monitoring in a tertiary care setting. Biopsies were scored using the NASH Clinical Research Network guidelines. Fibrosis regression was defined as improvement in fibrosis score ≥1 stage. Univariate analysis utilized Fisher’s exact or Student’s t test. Multivariate regression models determined independent predictors for regression of fibrosis.


Forty-five NASH patients with biopsies collected at a mean interval of 4.6 years (±1.4) were included. The mean initial fibrosis stage was 1.96, two patients had cirrhosis and 12 patients (26.7 %) underwent bariatric surgery. There was a significantly higher rate of fibrosis regression among patients who lost ≥10 % total body weight (TBW) (63.2 vs. 9.1 %; p = 0.001) and who underwent bariatric surgery (47.4 vs. 4.5 %; p = 0.003). Factors such as age, gender, glucose intolerance, elevated ferritin, and A1AT heterozygosity did not influence fibrosis regression. On multivariate analysis, only weight loss of ≥10 % TBW predicted fibrosis regression [OR 8.14 (CI 1.08–61.17)].


Results indicate that regression of fibrosis in NASH is possible, even in advanced stages. Weight loss of ≥10 % TBW predicts fibrosis regression.


Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis Fibrosis 



Alanine aminotransferase


American Association for the Study of Liver Diseases


Aspartate aminotransferase


Body mass index


Dartmouth–Hitchcock Medical Center


Institutional Review Board


Nonalcoholic fatty liver disease


Nonalcoholic steatohepatitis


NAFLD activity score


Statistical Package for the Social Sciences


Total body weight



The authors would like to thank Dr. Stephen Caldwell for his thoughtful review and input on the manuscript.

Conflict of interest

Dickson, disclosures for Gilead, BMS.


  1. 1.
    Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prevent Med. 2012;42:563–570.CrossRefGoogle Scholar
  2. 2.
    Bedogni G, Miglioli L, Masutti F, Teribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.CrossRefPubMedGoogle Scholar
  4. 4.
    Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–328.CrossRefPubMedGoogle Scholar
  5. 5.
    Charlton MR, Burns JM, Pederson RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.CrossRefPubMedGoogle Scholar
  6. 6.
    Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of non-alcoholic fatty liver disease. J Hepatol. 2005;42:132–138.CrossRefPubMedGoogle Scholar
  7. 7.
    McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40:S17–S29.PubMedGoogle Scholar
  8. 8.
    Argo CK, Northrup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371–379.CrossRefPubMedGoogle Scholar
  9. 9.
    Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77–85.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. NEJM. 2010;362:1675–1685.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Disease, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.CrossRefPubMedGoogle Scholar
  12. 12.
    Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49:80–86.CrossRefPubMedGoogle Scholar
  14. 14.
    Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100:1072–1081.CrossRefPubMedGoogle Scholar
  15. 15.
    Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647–1654.CrossRefPubMedGoogle Scholar
  16. 16.
    Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6:1396–1402.CrossRefPubMedGoogle Scholar
  17. 17.
    Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients (review). Cochrane Database Syst Rev. 2010;20(1):CD007340.Google Scholar
  18. 18.
    Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system of nonalcoholic fatty liver disease. Hepatology. 2005;41:1313.CrossRefPubMedGoogle Scholar
  19. 19.
    Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–1882.CrossRefPubMedGoogle Scholar
  20. 20.
    Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis. 2012;16:487–504.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Tendler D, Lin S, Yancy WS, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007;52:589–593.CrossRefPubMedGoogle Scholar
  22. 22.
    Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg. 2007;17:486–492.CrossRefPubMedGoogle Scholar
  23. 23.
    Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and metabolic syndrome. Ann Surg. 2005;242:610–617.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Furuya CK, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol. 2007;22:510–514.CrossRefPubMedGoogle Scholar
  25. 25.
    Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532–540.CrossRefPubMedGoogle Scholar
  26. 26.
    Kok KF, Wahab PJ, Houwen RH, et al. Heterozygous alpha-I antitrypsin deficiency as a co-factor in the development of chronic liver disease: a review. Neth J Med. 2007;65:160–166.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Lisa M. Glass
    • 1
    • 7
  • Rolland C. Dickson
    • 1
    • 5
    • 6
    Email author
  • Joseph C. Anderson
    • 2
  • Arief A. Suriawinata
    • 3
  • Juan Putra
    • 3
  • Brian S. Berk
    • 1
    • 4
  • Arifa Toor
    • 1
  1. 1.Section of GastroenterologyDartmouth–Hitchcock Medical CenterLebanonUSA
  2. 2.Section of GastroenterologyGeisel School of Medicine at DartmouthLebanonUSA
  3. 3.Department of PathologyDartmouth–Hitchcock Medical CenterLebanonUSA
  4. 4.St. Luke’s Clinic, GastroenterologyTwin FallsUSA
  5. 5.Department of MedicineGeisel School of Medicine at DartmouthLebanonUSA
  6. 6.Department of HepatologyDartmouth–Hitchcock Medical CenterLebanonUSA
  7. 7.Division of Gastroenterology and HepatologyUniversity of Michigan Health System, VA Ann Arbor Healthcare SystemAnn ArborUSA

Personalised recommendations